contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


cyxone-enters-important-research-collaboration

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Cyxone is a biotechnology company. The company's specialist expertise is found in the development of pharmaceuticals with a focus on plant protein as a base. The pharmaceutical is intended to be used mainly in the treatment of immune-related diseases, and the products are based on cyclotide technology. The purpose is that the pharmaceutical will be used in the treatment of multiple sclerosis and rheumatoid arthritis. Cyxone's head office is located in Malmö. 

Cyxone

Cyxone (publ), a biotech company in autoimmune diseases, enters into a strategically important research collaboration with an acknowledged research group at University of Glasgow, UK, with the...

<div class="abstract">Cyxone (publ), a biotech company in autoimmune diseases, enters into a strategically important research collaboration with an acknowledged research group at University of Glasgow, UK, with the objective of performing an exploratory phase 2 study with rabeximod in patients with rheumatoid arthritis (RA).<a href="https://cyxone.com/en/">https://cyxone.com/en/</a></div>The research group at School of Infection and Immunity, University of Glasgow is an internationally recognised centre of excellence conducting high quality basic, translational and clinical research in the disciplines of infection, immunology and inflammation. The collaboration will be performed together with members of the Glasgow Rheumatic and Musculoskeletal Disease Group which is a world leading centre in RA research and other immune-mediated inflammatory diseases.The researchers at the School of Infection and Immunity led by Professor Iain McInnes, also constitute one of the four corner stones of the consortium Research into Inflammatory Arthritis Centre Versus Arthritis&nbsp;(<a href="https://www.race-gbn.org/about/">https://www.race-gbn.org/about/</a>) (RACE), that together with the universities in Birmingham, Newcastle and Oxford have joined forces to perform translational research to gain a better understanding of the causes behind RA and how to treat it."We are excited to enter this research collaboration with the Cyxone team. It is a very interesting project that we see before us. And having followed the development of rabeximod over the years I am looking forward to now learn more about how the molecule works in greater detail", says Professor Iain McInnes, University of Glasgow."We are extremely pleased to be able to announce this strategically important collaboration around rabeximod. It is an honor that Cyxone now can establish this research collaboration with the University of Glasgow and their world-leading experts within RA research. With this, we will be able to learn much more about rabeximod and how the drug acts in the body by accessing the advanced state-of-the-art technologies that the scientists in Glasgow use in their research. The collaboration also provides access to the wider group of expertise that are in the British RA research consortium RACE, where a number of leading key opinion leaders take part, many of them already acquainted with Cyxone's project. We are really looking forward to this very important collaboration, and the learnings that will come out of it", says Carl-Magnus Högerkorp, CEO of Cyxone.ContactCarl-Magnus Högerkorp, CEO Tel: +46 (0)70 781 88 12 Email: carl.hogerkorp@cyxone.comAbout CyxoneCyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit www.cyxone.com

Stay up to date with our newsletter